Tirzepatide (Month 1) 2.5mg
US$ 21.27
is zepbound a glp-1 How It Works: Dual GLP-1/GIP Action Eli Lilly strikes Zepbound deal
Description
Available for both RF and RM licensing.
Aims/hypothesis Tirzepatide is a novel dual glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 receptor agonist (GLP-1 RA) currently under review for marketing approval
&srotate=0)
With the emergence of various classes of blood glucose-lowering agents, choosing the appropriate drug for each patient is emphasized in diabetes management
Encourages Satiety - GLP-1 support helps reduce appetite for weight management
While fasting GLP-1 remained largely unchanged, postprandial concentrations rose markedly at 6 months (total AUC increase in RYGB: ~330%, OAGB: ~259%
